文献速递炎症性肠病消化道肿瘤与早癌

CAR-T细胞治疗后免疫效应细胞介导的小肠结肠炎:临床特征、病理生理与管理

Review Article: Immune Effector Cell-Mediated Enterocolitis Following CAR-T Cell Therapy-Clinical Features, Pathophysiology and Management.
PubMed 文献 · Aliment Pharmacol Ther · 2026-08-13

本文综述CAR-T治疗后罕见并发症免疫效应细胞介导的小肠结肠炎(IEC-EC),发生率约6%,多见于BCMA靶向CAR-T后,表现为严重腹泻和吸收不良,治疗反应差、预后不良,需早期识别和多学科管理。

要点

  • IEC-EC发生率约6%,多见于BCMA靶向CAR-T治疗后。
  • 典型表现为严重腹泻和吸收不良,治疗反应差且预后不良。
  • 管理核心为早期诊断、支持治疗、感染评估及阶梯药物治疗。

核心结论

  • CAR-T治疗后出现胃肠道症状需高度警惕IEC-EC,早期识别和多学科治疗可能改善预后。

研究设计与样本

  • 本综述通过全面综合迄今文献中所有病例系列,呈现IEC-EC的当前知识状态。

主要发现

  • IEC-EC发生率高达约6%,通常发生于BCMA靶向CAR-T治疗后。
  • IEC-EC表现为严重腹泻和吸收不良,对治疗反应差,预后不良。

关键数值与推荐

  • 多学科管理应围绕早期诊断、支持治疗、感染评估与治疗以及阶梯药物治疗,常使用来自IBD药物库的生物制剂和小分子药物。

临床怎么用

  • 对CAR-T治疗后出现胃肠道症状的患者应高度警惕IEC-EC,早期识别并启动多学科治疗。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Chimeric antigen receptor T-cell (CAR-T) therapy has revolutionised the treatment of hematologic malignancies, and its use is expanding rapidly into numerous other disease states including autoimmune diseases. However, CAR-T therapy is associated with a spectrum of immune-related toxicities. In addition to the already well characterized cytokine release syndrome and immune effector cell-associated neurotoxicity syndrome, it has become apparent that rarely, CAR-T can cause gastrointestinal mucosal inflammation, termed immune effector cell-mediated enterocolitis (IEC-EC). AIMS: This state-of-the-art review highlights the CAR-T mechanism and details the epidemiology, pathophysiology, clinical manifestations, endoscopic and histopathologic features, and management of IEC-EC. METHODS: This review presents the current state of knowledge through a comperhensive and detailed synthesis of all case series reported in the literature to date. RESULTS: Occurring in up to approximately 6% of patients typically following B cell maturation antigen-targeted CAR-T therapy, IEC-EC presents with severe diarrhoea and malabsorption, responds poorly to treatment, and portends a dire prognosis. Multi-disciplinary management should centre on early diagnosis, supportive cares, assessment and treatment of infections, and step-up pharmacotherapy, often featuring biologics and small molecules drawn from the inflammatory bowel disease pharmacologic armamentarium. CONCLUSIONS: Clinicians should maintain a high degree of vigilance for IEC-EC in patients presenting with gastrointestinal symptoms following CAR-T treatment. Early recognition and multi-disciplinary treatment may improve patient outcomes.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Damianos JA, Lin Y, Chen ZE, et al. Review Article: Immune Effector Cell-Mediated Enterocolitis Following CAR-T Cell Therapy-Clinical Features, Pathophysiology and Management. Aliment Pharmacol Ther. 2026. PMID: 42596026. doi:10.1111/apt.70920

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。